Associate Professor
Pharmaceutical Sciences
Associate Professor
Anatomy and Neurobiology

MEMPHIS TN 381632198
Tel: (901) 448-2935

Current Lab Openings

We are recruiting self-motivated Postdoctoral Fellows and Ph.D. Students in CNS pharmacology. Should you be interested, please send the CV to jjiang18@uthsc.edu.

Advanced Education/Degrees

2008 – 2014    PostDoc, Emory University, Pharmacology & Neuroscience

2004 – 2008    Ph.D., Auburn University, Cellular & Molecular Biosciences

1996 – 1999    M.S., East China University of Science & Technology, Biochemistry

Positions in Academia/Pharmaceutical Industry

07/2018 – Present        Associate Professor, University of Tennessee (UT) College of Pharmacy

01/2015 – 06/2018      Assistant Professor, University of Cincinnati (UC) College of Pharmacy

01/2000 – 06/2004      R&D Project Supervisor, Shanghai RAAS Blood Products Co., Ltd.

Research Interest/Specialty

Neuropharmacology, CNS Drug Discovery, Neuroinflammation, and Chemical Neuroscience

Research Keywords

Blood-Brain Barrier; COX-2; Epilepsy; Glioma; GPCR; Microglia; PGE2; Seizure; Status Epilepticus

Research Description

The research in our laboratory is primarily dedicated to a better understanding of neuroinflammatory processes following brain insults such as prolonged seizures. We have also recently begun to explore the neuron-glia interactions in malignant gliomas, the most devastating brain tumors that constitute a major cause for epilepsy, particularly in the elderly. We attempt to unlock the cellular and molecular mechanisms whereby normal brains are transformed to generate spontaneous recurrent seizures, i.e., acquired epileptogenesis. We are also interested in developing novel antiepileptic and/or antiepileptogenic therapeutics in close collaboration with medicinal chemistry laboratories. To achieve these goals, we use a variety of technologies and experimental systems, such as high-throughput screening, chemical genetics, TR-FRET, RNAi, CRISPR/Cas9, microdialysis, time-locked video EEG, behavioral tests, etc.

Current Research Support (as PI)

  • Prostaglandin signaling following seizures, NIH/NINDS, R00NS082379, $747,000, 07/01/2015 – 12/31/2019, 15% effort
  • Inflammatory regulation of neurotrophin signaling in epileptogenesis, NIH/NINDS, R01NS100947, $1,679,396, 12/01/2017 – 11/30/2022, 30% effort
  • Targeting prostaglandin receptor EP2 for glioma and associated epilepsy, NIH/NINDS, R21NS109687, $418,000, 01/01/2019 – 12/31/2020, 25% effort

Selected Honors

2016       UC Health Research Rising Star Award

2014       NARSAD Young Investigator Award

2013       NIH Pathway to Independence Award

2013       SfN Postdoctoral Fellow Travel Award

2013       Emory University Outstanding Postdoctoral Fellow

2012       Epilepsy Foundation Postdoctoral Research Fellowship

2011       NIH/NIMH Julius Axelrod Travel Award

2010       NIH/NINDS CounterACT Program Travel Award

2007       Kenneth Ottis Distinguished Graduate Fellowship

1998       BASF Graduate Scholarship

Patents Granted/in Application

Selected Publications (*Correspondence)

  1. Dawn A, Yao X, Yu Y, Jiang J* and Kumari H* (2019) Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application. Supramolecular Chemistry 7:425-431.
  2. Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y, Shi Z* and Jiang J* (2019) Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. British Journal of Pharmacology 176:1680-1699.
  3. Jiang J*, Yu Y, Kinjo ER, Du Y, Nguyen HP and Dingledine R (2019) Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology 149:149-160.
  4. Jiang J*, Van TM, Ganesh T and Dingledine R (2018) Discovery of 2-piperidinyl phenyl benzamides and trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2. ACS Chemical Neuroscience 9:699-707.
  5. Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, Winkler MKL, Major S, Horst V, Jahnke P, Woitzik J, Kola V, Du Y, Hagen M, Jiang J and Dreier JP (2017) Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain 140:2673-2690.
  6. Kang X, Qiu J, Li Q, Bell KA, Du Y, Jung DW, Lee JY, Hao J and Jiang J* (2017) Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports 7:9459.
  7. Jiang J*, Qiu J, Li Q and Shi Z* (2017) Prostaglandin E2 signaling: alternative target for glioblastoma? Trends in Cancer 3:75-78.
  8. Qiu J, Shi Z* and Jiang J* (2017) Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today 22:148-156.
  9. Dey A, Kang X, Qiu J, Du Y and Jiang J* (2016) Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends in Pharmacological Sciences 34:413-423.
  10. Du Y, Kemper T, Qiu J and Jiang J* (2016) Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Review of Neurotherapeutics 16:123-130.
  11. Du Y, Seibenhener ML, Yan J, Jiang J and Wooten MC (2015) aPKC phosphorylation of HDAC6 results in increased deacetylation activity. PLOS ONE 10:e0123191.
  12. Fu Y, Yang M-S, Jiang J, Ganesh T, Joe E and Dingledine R (2015) EP2 receptor signaling regulates microglia death. Molecular Pharmacology 88:161-170.
  13. Jiang J*, Yang M-S, Quan Y, Gueorguieva P, Ganesh T and Dingledine R (2015) Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease 76:126-135.
  14. Varvel NH*, Jiang J* and Dingledine R* (2015) Candidate drug targets for prevention or modification of epilepsy. Annual Review of Pharmacology and Toxicology 55:229-247.
  15. Ganesh T, Jiang J and Dingledine R (2014) Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry 82:521-535.
  16. Ganesh T, Jiang J, Yang M and Dingledine R (2014) Lead optimization studies of cinnamic amide EP2 antagonists. Journal of Medicinal Chemistry 57:4173-4184.
  17. Rojas A, Jiang J, Ganesh T, Yang M, Lelutiu N, Gueorguieva P and Dingledine R (2014) Cyclooxygenase-2 in epilepsy. Epilepsia 55:17-25.
  18. Yan J, Seibenhener ML, Calderill-Barbosa L, Diaz-Meco MT, Moscat J, Jiang J, Wooten MW and Wooten MC (2013) SQSTM1/p62 interacts with HDAC6 and regulates deacetylase activity. PLOS ONE 8:e76016.
  19. Ganesh T*, Jiang J*, Shashidharamurthy R and Dingledine R (2013) Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. ACS Medicinal Chemistry Letters 4:616-621.
  20. Jiang J* and Dingledine R* (2013) Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharmacological Sciences 34:413-423.
  21. Seibenhener ML, Zhao T, Du Y, Calderill-Barbosa L, Yan J, Jiang J, Wooten MW and Wooten MC (2013) Behavioral effects of SQSTM1/p62 overexpression in mice: Support for a mitochondrial role in depression and anxiety. Behavioural Brain Research 248:94-103.
  22. Quan Y, Jiang J and Dingledine R (2013) EP2 receptor signaling pathways regulate classical activation of microglia. Journal of Biological Chemistry 288:9293-9302.
  23. Jiang J*, Quan Y, Ganesh T, Pouliot WA, Dudek FE and Dingledine R (2013) Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proceedings of the National Academy of Sciences of the USA 110:3591-3596.
  24. Jiang J* and Dingledine R (2013) Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. Journal of Pharmacology and Experimental Therapeutics 344:360-367.
  25. Jiang J*, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N and Dingledine R* (2012) Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the USA 109:3149-3154.
  26. Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A and Dingledine R (2010) Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the USA 107:2307-2312.
  27. Jiang J, Parameshwaran K, Seibenhener ML, Kang MG, Suppiramaniam V, Huganir RL, Diaz-Meco MT and Wooten MW (2009) AMPA receptor trafficking and synaptic plasticity require SQSTM1/p62. Hippocampus 19:392-406.
  28. Traffina J, Geetha T, Jiang J and Wooten MW (2008) Identification of a conserved consensus site for TRAF6/p62 substrate polyubiquitination. Biochemical and Biophysical Research Communications 371:521-524.
  29. Jiang J, Suppiramaniam V and Wooten MW (2006-2007) Posttranslational modifications and receptor-associated proteins in AMPA receptor trafficking and synaptic plasticity. NeuroSignals 15:266-282.
  30. Geetha T, Jiang J and Wooten MW (2005) Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Molecular Cell 20:301-312.

Full Publications

Google Scholar          My NCBI          NeuroTree